1. Classify the importance of accurate blood pressure measurement, medication adherence, and lifestyle modifications that impact blood pressure.

2. Evaluate secondary causes of resistant hypertension (RHTN).

3. Assess the drug therapy options for treatment of RHTN.

4. Analyze the newly approved and in-pipeline pharmacologic treatment options for RHTN.

5. Assess the different procedural interventions approved or in-pipeline for managing RHTN.

6. Develop a pharmacologic treatment plan for a patient with RHTN based on the latest guideline recommendations.

1. Assess drug therapies for heart failure (HF) with ejection fraction (EF) greater than 40%.

2. Distinguish the differences in the drug therapy recommendations from the latest and leading guidelines for HF with EF greater than 40%, and distinguish from recommendations for HF with reduced EF.

3. Develop a pharmacologic treatment plan for HF with EF greater than 40% that optimizes the use of guideline-directed medical therapy.

4. Develop an outpatient diuretic and fluid management plan for HF.

5. Resolve practical issues in the pharmacologic management of HF.

1. Evaluate the clinical use of cardiovascular risk stratification methods to guide preventive and therapeutic recommendations.

2. Assess cardiovascular risk to determine actionable risk modification strategies.

3. Design patient-specific care plans that include nonpharmacologic therapies to reduce cardiovascular risk.

4. Justify cardiovascular risk modification strategies in patients with comorbid chronic disease states such as type 2 diabetes, hypertension, dyslipidemia, and tobacco use disorder.

1. Assess the differences between attention-deficit/hyperactivity disorder (ADHD) between adult and pediatric presentations.

2. Analyze the available treatment guidelines for adult and pediatric ADHD.

3. Distinguish the difference between newer pharmacologic options and older agents.

4. Evaluate current evidence-based literature comparing ADHD medications to establish an appropriate treatment plan.

5. Devise a treatment plan for ADHD accounting for adverse effects and monitoring.

1. Evaluate the screening, brief intervention, referral to treatment (SBIRT) model for youth with substance use disorders (SUDs).

2. Distinguish between hallmark features of cannabis use disorder, nicotine use disorder, alcohol use disorder, opioid use disorder, and stimulant use disorder.

3. Analyze the role of medication treatment for SUD.

4. Develop a monitoring plan and appropriate treatment/supportive care recommendations for withdrawal symptoms.

5. Evaluate the role of harm reduction strategies to support pediatric patients.

1. Estimate frailty through evaluation of patient risk factors and available screening tools.

2. Evaluate a patient’s medication regimen for appropriate and potentially inappropriate medications.

3. Design a tailored plan considering nonpharmacologic and pharmacologic interventions for a frail patient with hypertension, diabetes, or insomnia.

4. Analyze fall, fracture, or bleeding risk for a frail patient to implement appropriate risk mitigation strategies.

1. Distinguish the differences in treatments for the management of overweight and obesity.

2. Assess and design a pharmacotherapy plan for a patient with overweight or obesity given patient-specific factors.

3. Devise monitoring values to determine the efficacy and safety of anti-obesity pharmacotherapy.

4. Evaluate available literature to bridge gaps in knowledge with emerging evidence.

1. Discover resources for interpreting and applying pharmacogenomic results to prescribing decisions.

2. Assess the impact of a pharmacogenomic result on a medication outcome.

3. Design a pharmacogenomic-informed care-plan for personalized treatment.

4. Evaluate strategies and best practices for integrating pharmacogenomic results into primary care workflows.

5. Detect ethical, legal, and social considerations for integrating pharmacogenomics in primary care.